Last reviewed · How we verify
Epifasi: Human chorionic gonadotrophin
Epifasi, a human chorionic gonadotrophin drug marketed by Genuine Research Center, Egypt, holds a niche position in the pharmaceutical market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue protection. However, the lack of detailed clinical trial results and primary indication data poses a significant risk to its market acceptance and competitive positioning.
At a glance
| Generic name | Epifasi: Human chorionic gonadotrophin |
|---|---|
| Also known as | Epifasi |
| Sponsor | Genuine Research Center, Egypt |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women (PHASE3)
- Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles (NA)
- Biosimilarity Study of IM Injection of Human Chorionic Gonadotrophin After Parenteral Administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter Pharmaceutical Solutions for Organon, USA). (PHASE4)
- Trans-vaginal Aspiration of Small Ovarian Endometrioma. Comparison of Two Different Techniques Before ICSI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: